对2型糖尿病抗糖尿病药物的认知结果进行比较:系统性审查和网络元分析
Sai Tian1,2, Jiaxuan Jiang1,2, Jin Wang1,2
1Department of Endocrinology, Endocrine and Metabolic Disease Medical Center, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Diabetes/metabolism research and reviews
|June 11, 2023
概括
某些抗糖尿病药物,如SGLT-2抑制剂和GLP-1RA,可以降低2型糖尿病患者的痴呆风险. 硫尿素与风险增加有关,这表明治疗选择会影响认知健康.
科学领域:
- 内分泌学和神经病学 在内分泌学和神经病学.
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 2型糖尿病 (T2DM) 与认知障碍 (包括痴呆症) 的风险增加有关.
- 确定治疗策略以减轻T2DM患者的认知衰退对于公共卫生至关重要.
结论:
- 在推迟T2DM患者的认知障碍和痴呆症方面,SGLT-2i和GLP-1RA似乎最有效.
- 对于T2DM管理的药物选择可能会影响长期的认知结果.
- 进一步的研究应该集中在这些抗糖尿病药物的神经保护机制上.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
240
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
240
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
218
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
218
Oral Hypoglycemic Agents: Glinides
190
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
190
Diabetes: Management and Pharmacotherapy
319
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
319
Diabetes Mellitus: Type 2 and Gestational
2.6K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.6K
Diabetes Mellitus: Overview and Type I Subtype
2.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.8K


